MRIC - MRI Interventions, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.1900
0.0000 (0.00%)
As of 3:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.1900
Open3.1300
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.1900 - 3.1900
52 Week Range1.3300 - 3.7400
Volume3,688
Avg. Volume16,453
Market Cap43.045M
Beta (3Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.5220
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    MRI Interventions Announces Closing of $7.522 Million Private Placement

    MRI Interventions, Inc. (MRIC) today announced the closing on May 17, 2019 of its previously disclosed private placement of shares of common stock, which resulted in gross proceeds of $7.522 million. The 2,426,455 shares of MRI Interventions’ common stock were sold at a negotiated price of $3.10 per share. The securities offered and sold by MRI Interventions in the private placement were not registered under the Securities Act of 1933 or state securities laws and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission or an applicable exemption from such registration requirements.

  • PR Newswire2 months ago

    PTC Therapeutics and MRI Interventions Announce Strategic Investment

    SOUTH PLAINFIELD, N.J. and IRVINE, Calif., May 9, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) and MRI Interventions, Inc. (MRIC) today announced a strategic equity investment, with PTC purchasing $4.0 million in shares of MRI common stock. PTC and MRI have also entered into a supply agreement for MRI's neurosurgical devices for PTC's current and future gene therapy programs. MRI is a platform neurosurgery company developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene therapy.

  • GlobeNewswire2 months ago

    MRI Interventions Reports 52% Increase in First Quarter Revenue

    IRVINE, Calif., April 30, 2019 -- MRI Interventions, Inc. (OTCQB: MRIC) (the “Company”) today announced financial results for its first fiscal quarter ended March 31, 2019..

  • ACCESSWIRE2 months ago

    MRI Interventions, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 30, 2019 / MRI Interventions, Inc. (OTCQB: MRIC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 30, 2019 at 4:30 PM ...

  • GlobeNewswire2 months ago

    MRI Interventions, Inc. to Announce First Quarter 2019 Results on April 30

    MRI Interventions, Inc. (MRIC), a platform neurosurgery company with products designed to deliver navigation, ablation, deep brain stimulation, biopsy and gene therapy, today announced that it will release financial results for its 2019 first quarter, which ended March 31, 2019, on Tuesday, April 30, 2019 after the market close. Statements herein concerning MRI Interventions, Inc.’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws.

  • GlobeNewswire3 months ago

    MRI Interventions Congratulates Dr. Clark Chen On First Patient Dosing In Minnesota For Phase 2 Glioblastoma Trial

    “We commend Dr. Chen on this significant milestone in his clinical program,” commented Zach Carr, Portfolio Manager for Biologics and Drug Delivery at MRI Interventions. “The ability for MRI Interventions to work closely with cutting edge therapies and premier academic centers continues to position us and our expertise in the biologic space.

  • OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference
    PR Newswire3 months ago

    OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

    OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ --  OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...

  • GlobeNewswire3 months ago

    MRI Interventions Reports 36% Increase in Fourth Quarter Revenue and Record Quarterly ClearPoint® Cases

    IRVINE, Calif., March 11, 2019 -- MRI Interventions, Inc. (OTCQB: MRIC) (the “Company”) today announced financial results for its fourth fiscal quarter and full year ended.

  • GlobeNewswire3 months ago

    MRI Interventions Announces Collaboration with Voyager Therapeutics for the Design, Manufacture and Supply of V-TAG™ Device

    MRI Interventions, Inc. (MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager Therapeutics, Inc. (VYGR) to design, manufacture and supply the Variable Trajectory Array Guide, or V-TAG, neurosurgical device for Voyager.  Under the collaboration, Voyager transferred its existing 510(k) clearance for the V-TAG device to MRI Interventions who will manufacture and supply the device as a choice for neurosurgeons, along with MRI’s Clearpoint® system, for use in Voyager’s RESTORE-1 Phase 2 trial of its VY-AADC gene therapy program for Parkinson’s disease. “We continue to evolve and expand our relationship with Voyager with the common goal of delivering gene therapy to specific regions of the brain with accuracy to give our patients the best possible chance at success,” commented Joe Burnett, President and CEO at MRI Interventions.

  • GlobeNewswire4 months ago

    MRI Interventions Announces Agreement with Siemens Healthineers For Interfacing with the Portfolio of Magnetom MRI Scanners

    MRI Interventions, Inc. (MRIC), a platform neurosurgery company developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene therapy, today announced a collaborative agreement with Siemens Healthineers for the integration of the ‘Access-I’ software solution available on the Magnetom family of scanners worldwide with MRI Interventions’ ClearPoint® Neuro Navigation System. This advanced level of access and compatibility will facilitate faster pre-planning and peri-procedural data transfer to and from the ClearPoint System for use in both navigation and therapy procedures. “As the movement toward minimally invasive neurosurgery continues, we have the opportunity to be leaders in defining the workflows that will be utilized in the future,” commented Joe Burnett, President and CEO of MRI Interventions.

  • GlobeNewswire4 months ago

    MRI Interventions, Inc. to Announce Fourth Quarter and Full Year 2018 Results on March 11

    MRI Interventions, Inc. (MRIC), a platform neurosurgery company with products designed to deliver navigation, ablation, deep brain stimulation, biopsy and gene therapy, today announced that it will release financial results for its 2018 fourth quarter and full year, which ended December 31, 2018, on Monday, March 11, 2019 after the market close. Statements herein concerning MRI Interventions, Inc.’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws.

  • GlobeNewswire4 months ago

    MRI Interventions to Host Meetings at Roth Capital Conference on March 18

    MRI Interventions, Inc. (MRIC), a platform neurosurgery company with products designed for navigation in procedures for deep brain stimulation, ablation, aspiration and gene therapy, today announced that Joe Burnett, CEO, will host investor meetings at the 31st Annual Roth Capital Conference on Monday, March 18, 2019. The Company previously announced that it anticipates revenue for the quarter ended December 31, 2018 to be approximately $2.2 million, an increase of 30% from $1.7 million in the prior year fourth quarter, driven by a record 188 procedures using the company’s ClearPoint Neuro Navigation System in the 2018 fourth quarter. Cash used in operations declined to approximately $600,000, compared with $1.7 million used in the year-ago fourth quarter and better than the company’s expected usage of $800,000 for the quarter.

  • GlobeNewswire6 months ago

    MRI Interventions Announces Estimated 30% Growth Driven by Record Revenue and Record ClearPoint® Procedure Volume in 2018 Fourth Quarter

    MRI Interventions, Inc. (MRIC), a platform neurosurgery company with products designed for navigation in procedures for deep brain stimulation, ablation, aspiration and gene therapy, today announced preliminary and unaudited results for the quarter ended December 31, 2018, and expectations for fiscal 2019 revenue and cases. Revenue for the quarter ended December 31, 2018 is expected to be approximately $2.2 million, an increase of 30% from $1.7 million in the prior year fourth quarter. This increase was due primarily to a record 188 procedures using the company’s ClearPoint Neuro Navigation System in the 2018 fourth quarter.

  • GlobeNewswire6 months ago

    MRI Interventions Receives FDA Clearance for ClearPoint® PURSUIT™ Neuro Aspiration System

    MRI Interventions, Inc. (MRIC), a platform neurosurgery company with products designed for navigation in procedures involving deep-brain stimulation, ablation, and gene and drug delivery today announced FDA Clearance of the ClearPoint PURSUIT Neuro Aspiration system. The PURSUIT device was designed in collaboration with the Mayo Clinic and represents the first internally developed therapeutic product added to the MRI Interventions platform portfolio. The ClearPoint PURSUIT neuro aspiration device is indicated for the controlled aspiration of blood, clotted blood, cystic components of tumors, abscesses, colloid cysts, and cerebral spinal fluid using a manual syringe during the surgery of the ventricular system or cerebrum.

  • GlobeNewswire6 months ago

    MRI Interventions Congratulates Voyager Therapeutics on First Patient Dosing in RESTORE-1, the Phase 2 VY-AADC Gene Therapy Trial for Parkinson’s Disease

    Under the agreement with Voyager, MRI Interventions provided the navigation system and drug infusion cannulae, as well as clinical support during the procedure to assist the Voyager team in executing the clinical protocol. “Patients with Parkinson’s disease need new therapeutic options, especially as the disease progresses and there is less AADC enzyme in parts of the brain where it is needed to convert levodopa to dopamine,” said Mark Richardson, M.D., Ph.D., Associate Professor, Director of Epilepsy and Movement Disorders Surgery at the University of Pittsburgh Medical Center and principal investigator in the RESTORE-1 trial.

  • GlobeNewswire7 months ago

    MRI Interventions Reports Record ClearPoint® Cases and Disposable Functional Neurosurgery Revenue in Third Quarter

    IRVINE, Calif., Nov. 12, 2018 -- MRI Interventions, Inc. (OTCQB: MRIC) (the “Company”) today announced financial results for its third fiscal quarter ended September 30, 2018..

  • GlobeNewswire8 months ago

    MRI Interventions Announces FDA Clearance of ClearPoint® 2.0 Next-Generation Software Platform

    MRI Interventions, Inc. (MRIC) today announced FDA clearance for the company’s latest software platform – ClearPoint® 2.0. The platform’s new features are designed to improve the clinical workflow and user experience of the company’s ClearPoint Neuro Navigation System, including enhanced functionality in areas of image fusion, volume of interest display and measurement, 3D image visualization and multi-trajectory planning. “ClearPoint 2.0 is a generational upgrade that has been years in the making,” commented Joe Burnett, President and CEO of MRI Interventions.

  • GlobeNewswire8 months ago

    MRI Interventions, Inc. to Announce Third Quarter 2018 Results on November 12

    IRVINE, Calif., Nov. 05, 2018 -- MRI Interventions, Inc. (OTCQB:MRIC) announced that it will release financial results for its 2018 third quarter, which ended September 30,.